PhRMA

12/31/2025

2025 in Review: Our innovation series followed our members as they made bold investments in American medical innovation and manufacturing — opening new facilities, expanding their workforce, and accelerating the advanced R&D and production that strengthen America’s global leadership.

A year marked by growth, momentum, and putting American patients first.

https://innovation.org/american-investment/

12/30/2025

As we look back on the year, one theme stands out: Biopharma is investing big in America’s future.

Biopharmaceutical companies have committed over $500 billion to new research hubs, advanced manufacturing and workforce development — strengthening our ability to lead the world in medical innovation. These investments fuel the treatments of tomorrow and support communities across the country today.

See how continued U.S. leadership is being built.

The biopharmaceutical industry is on the brink of unprecedented breakthroughs, with the potential to revolutionize health care, reduce the burden of disease

12/25/2025

340B hospitals can buy medicines at steep discounts, markup the price by thousands of dollars and pocket the difference. It’s time for Congress to put big hospitals on the Naughty List and reform 340B.

https://phrma.org/blog/one-thing-the-senate-can-agree-on-it-s-time-to-fix-340b

12/24/2025

PBMs have made their wishlist clear — more control, more restrictions, and higher costs for patients.

The three largest PBMs have excluded 8,895 medicines from commercial formularies since 2014, with 1,453 exclusions in 2025 alone. And now they’re buying up insurers and doctors’ offices to tighten their grip even further.

It’s up to policymakers to stop it.

https://phrma.org/policy-issues/pbms-middlemen

12/23/2025

Medicines are complex products made up of many inventions that are researched and improved over time.

Read more about the post-approval process here:

https://phrma.org/blog/how-post-approval-innovation-keeps-delivering-for-patients

12/18/2025

Three years into implementation of the IRA, the evidence is clear: government price-setting is chilling medical innovation, halting clinical trials and undermining patient access to innovative treatments.

Take a look at the facts.

12/15/2025

A new PILMA study highlights how America’s biopharmaceutical investment creates opportunity far beyond new medicines.

By building and maintaining manufacturing facilities and R&D labs, our industry provides a vital on-ramp to economic security for union construction workers in the building trades and their families.

And this has a ripple effect, because these jobs fuel local economies and strengthen communities throughout the area.

https://www.innovation.org/casestudy/american-infrastructure-investment/

12/10/2025

Too many Americans struggle to afford their medicines because of an insurance system that pushes patients into higher out-of-pocket costs, denials and delays.

While insurers and PBMs have excluded more medicines from their formularies each year, biopharmaceutical companies are stepping in with direct purchase options and patient support programs that help millions of Americans access the treatments they need.

Launching in January 2026, AmericasMedicines.com will provide a site to find direct purchase and patient support programs. But for now, check out PhRMA’s Medicine Assistance Tool to find patient support available to you.

12/09/2025

Patents filed after FDA approval represent new innovations that can reduce side effects, increase competition and broaden treatment options—enhancing patient care without lengthening the original patent term. Learn what critics get wrong about post-approval innovation:

https://phrma.org/blog/how-post-approval-innovation-keeps-delivering-for-patients

12/06/2025

Washington is searching for ways to lower drug costs, but price setting is not the answer. Three years under the IRA’s price setting policies and patients are experiencing higher out-of-pocket costs, more coverage denials and fewer plan choices. That’s because the law does nothing to rein in insurers and PBMs that decide what medicines patients can get and how much they pay.

If policymakers want real affordability, the answer is clear: rein in the middlemen driving up costs, don’t expand a policy that’s failing patients.

12/04/2025

Hepatitis B is serious — but preventable with early protection.

Chief Medical Officer Dr. Mike Ybarra breaks down why the hepatitis B vaccine shortly after birth is one of the most effective ways to protect newborns from lifelong liver disease.

Learn more from Dr. Ybarra.

https://phrma.org/blog/why-the-hepatitis-b-vaccine-matters

12/04/2025

The recommended vaccine schedule isn’t arbitrary—it reflects years of research on when kids are most vulnerable to serious illness. Combination vaccines help families stay on track with fewer appointments and fewer needles. Learn more about the evidence behind vaccine schedules from CMO Dr. Mike Ybarra.